C21 · Pharmaceuticals · China
Negotiated or bid drugs added to national reimbursement drug list (annual)
China: 89 in 2024.
- 89 Latest · China · 2024
- Annual Release cadence
- 1 Record · 1 region · 2024
Verified 17 Sep 2026 · 1 publisher · Next period 2025
The figure
One published observation so far. A chart follows as soon as a second period is published.
Negotiated or bid drugs added to national reimbursement drug list (annual)
China, 2024
Every record
1 record · 1 region · 2024. Each period links to its record: the value, its source evidence and original document.
| Period | Value | Source | Type |
|---|---|---|---|
| China 1 record | |||
| 2024 | 89 | State Council · 31 Dec 2024 | |
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: State Council. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (State Council); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Number of drugs admitted to a national reimbursement drug list through price negotiations or competitive bidding.
- Measure
- One slice of Formulary additions ( counting rule: negotiated or bid, form: count ) . Total number of new pharmaceutical products added to a reimbursement formulary or drug list. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 1 document
| Document | Publisher | Published | Data points |
|---|---|---|---|
| 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网 | State Council | — | 1 |
Other slices of formulary additions
- Newly added drugs in national reimbursement drug list 3
- Innovative drugs added to national health insurance catalog 2 innovative
- Newly added drugs in national reimbursement drug list (annual) 2
- Category 1 innovative drugs added to national health insurance catalog 1 category 1 innovative
- Centralized procurement drugs added to national reimbursement drug list 1 centralized procurement
- Cumulative drugs added via negotiation in reimbursement drug list 1 cumulative · negotiated
- Cumulative newly added drugs in reimbursement drug list 1 cumulative
- Globally new innovative drugs added to reimbursement drug list 1 globally new
- Innovative drugs added to national health insurance drug list 1 cumulative · innovative
- Medicines added to national health insurance drug list 1 cumulative
- Negotiated or bid drugs added to national reimbursement drug list 1 negotiated or bid
Frequently asked questions
What is the latest negotiated or bid drugs added to national reimbursement drug list (annual)?
China: 89 in 2024.
Where does this data come from?
From 1 document published by State Council. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Annual. The newest published period is 2024; the next release should cover 2025. A new figure appears here once the publisher releases it and it passes verification.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Negotiated or bid drugs added to national reimbursement drug list (annual) [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/negotiated-or-bid-drugs-added-to-national-reimbursement-drug-list-annual
"Negotiated or bid drugs added to national reimbursement drug list (annual)." StatOrigin, 2026, https://statorigin.org/indicators/negotiated-or-bid-drugs-added-to-national-reimbursement-drug-list-annual. Accessed 28 Oct. 2026.
StatOrigin. "Negotiated or bid drugs added to national reimbursement drug list (annual)." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/negotiated-or-bid-drugs-added-to-national-reimbursement-drug-list-annual.
@misc{statorigin_negotiated_or_bid_drugs_added_to_national_reimbursement_drug_list_annual_2026, title = {Negotiated or bid drugs added to national reimbursement drug list (annual)}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/negotiated-or-bid-drugs-added-to-national-reimbursement-drug-list-annual}, note = {Data set. Accessed 2026-10-28} }